Jump to content

Bismuth subcitrate: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
Next edit →
Content deleted Content added
VisualWikitext
New stub
 
+
Line 35: Line 35:
| excretion =
| excretion =
<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number =
| CAS_number = 880149-29-1
| class =
| class =
| ATCvet =
| ATCvet =
Line 41: Line 41:
| ATC_suffix = BX05
| ATC_suffix = BX05
| PubChem =
| PubChem =
| DrugBank =
| DrugBank = DB09275
| ChemSpiderID = 32821371
| ChemSpiderID = 32821371
| KEGG = D09739
<!-- Chemical and physical data -->
<!-- Chemical and physical data -->
| chemical_formula =
| chemical_formula =
| C=12 | H=9 | Bi=1 | K=3 | O=14
| C=12 | H=9 | Bi=1 | K=3 | O=14
| molecular_weight =
| molecular_weight =
| smiles = C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].[K+].[K+].[K+].[Bi+3]
| smiles = C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].[K+].[K+].[K+].[Bi+3]
| StdInChI=1S/C6H8O7.C6H7O7.Bi.3K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;/q;-1;+3;3*+1/p-6
| StdInChI=1S/C6H8O7.C6H7O7.Bi.3K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;/q;-1;+3;3*+1/p-6
Line 52: Line 53:
}}
}}


'''Bismuth subcitrate''' is a [[bismuth]] salt used in combination with antibiotics and a [[proton pump inhibitor]] for the treatment of ''[[Helicobacter pylori]]'' infections.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500005327.pdf|title=P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended|publisher=[[European Medicines Agency]]|date=2009-06-10}}</ref>
'''Bismuth subcitrate potassium''' is a [[bismuth]] salt used in combination with antibiotics and a [[proton pump inhibitor]] for the treatment of ''[[Helicobacter pylori]]'' infections.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500005327.pdf|title=P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended|publisher=[[European Medicines Agency]]|date=2009-06-10}}</ref><ref name=Urgesi2012>{{cite journal|last=Urgesi|first=Riccardo|last2=Cianci|first2=Rossella|last3=Riccioni|first3=Maria Elena|title=Update on triple therapy for eradication of Helicobacter pylori: current status of the art|year=2012|journal=Clinical and Experimental Gastroenterology|volume=5|pages=151–157|doi=10.2147/CEG.S25416}}</ref>


==See also==
==See also==

Revision as of 10:00, 24 October 2017

Bismuth subcitrate
Clinical data
ATC code
Identifiers
  • 1,2,3-Propanetricarboxylate, 2-hydroxy- 2-olato-1,2,3-propanetricarboxylate, bismuth(3+) potassium salt (1:1:1:3)
CAS Number
DrugBank
ChemSpider
KEGG
ECHA InfoCard100.055.320 Edit this at Wikidata
Chemical and physical data
FormulaC12H9BiK3O14
Molar mass703.465 g·mol−1
3D model (JSmol)
  • C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].[K+].[K+].[K+].[Bi+3]
  • InChI=1S/C6H8O7.C6H7O7.Bi.3K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;/q;-1;+3;3*+1/p-6
  • Key:MMJQTYCCEVUELA-UHFFFAOYSA-H

Bismuth subcitrate potassium is a bismuth salt used in combination with antibiotics and a proton pump inhibitor for the treatment of Helicobacter pylori infections.[1][2]

See also

References

  1. ^ "P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended" (PDF). European Medicines Agency. 2009-06-10.
  2. ^ Urgesi, Riccardo; Cianci, Rossella; Riccioni, Maria Elena (2012). "Update on triple therapy for eradication of Helicobacter pylori: current status of the art". Clinical and Experimental Gastroenterology. 5: 151–157. doi:10.2147/CEG.S25416.{{cite journal}}: CS1 maint: unflagged free DOI (link)


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bismuth_subcitrate&oldid=806817306"